EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
Tuesday, July 5, 2011 - 04:00
in Health & Medicine
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).